Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -31.52% is 12% above its 2-year average of -35.86%, near the high end of its 2-year range (-52.84%–-22.82%).
7.66% below its 12-month average of -29.28%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -22.82%.
EBITDA MARGIN
-31.52%
EBITDA MARGIN AVG TTM
-29.28%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-7.66%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Heartflow, Inc. Common Stock
Market Cap
$4.52B
EBITDA Margin
-31.52%
TTM Avg
-29.28%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.47B
EBITDA Margin
23.00%
TTM Avg
14.06%
3Y Avg
2.00%
5Y Avg
2.94%
Market Cap
$4.66B
EBITDA Margin
-14.19%
TTM Avg
-47.13%
3Y Avg
-77.82%
5Y Avg
-97.39%
Market Cap
$4.71B
EBITDA Margin
5.54%
TTM Avg
4.34%
3Y Avg
-4.50%
5Y Avg
-6.75%
Market Cap
$4.80B
EBITDA Margin
-8718.32%
TTM Avg
-5172.73%
3Y Avg
-3124.55%
5Y Avg
-2649.58%
Market Cap
$4.21B
EBITDA Margin
-250.61%
TTM Avg
-502.94%
3Y Avg
-374.26%
5Y Avg
-228.13%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Heartflow, Inc. Common Stock (HTFL) | $4.52B | -31.52% | -29.28% | N/A | N/A |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.47B | 23.00% | 14.06% | 2.00% | 2.94% |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.66B | -14.19% | -47.13% | -77.82% | -97.39% |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.33B | N/A | N/A | N/A | N/A |
| LifeStance Health Group, Inc. (LFST)vs › | $4.71B | 5.54% | 4.34% | -4.50% | -6.75% |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.73B | N/A | N/A | N/A | N/A |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.80B | -8718.32% | -5172.73% | -3124.55% | -2649.58% |
| AbCellera Biologics Inc. (ABCL)vs › | $4.21B | -250.61% | -502.94% | -374.26% | -228.13% |
| LivaNova PLC (LIVN)vs › | $4.18B | 17.39% | 15.89% | 7.31% | 2.27% |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.90B | 0.40% | -9.29% | -59.36% | -227.69% |
Gross Margin
80.1%
EBITDA Margin
-31.5%
Operating Margin
-34.3%
Net Margin
-55.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -22.82% |
| 2026-03-31 | -37.25% |
| 2025-12-31 | -31.56% |
| 2025-09-30 | -28.12% |
| 2025-06-30 | -26.64% |
| 2025-03-31 | -41.41% |
| 2024-12-31 | -39.23% |
| 2024-09-30 | -39.04% |
| 2024-06-30 | -39.68% |
| 2024-03-31 | -52.84% |
